These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31367864)

  • 21. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway.
    Tey SK; Tse EYT; Mao X; Ko FCF; Wong AST; Lo RC; Ng IO; Yam JWP
    Cancer Lett; 2017 Dec; 411():150-161. PubMed ID: 28989054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telmisartan-Induced Cytotoxicity via G
    Tsujiya Y; Hasegawa A; Yamamori M; Okamura N
    Biol Pharm Bull; 2021; 44(12):1878-1885. PubMed ID: 34853271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
    Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway.
    Yue P; Gao ZH; Xue X; Cui SX; Zhao CR; Yuan Y; Yin Z; Inagaki Y; Kokudo N; Tang W; Qu XJ
    Eur J Cancer; 2011 May; 47(7):1115-24. PubMed ID: 21349701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Albendazole-loaded cubosomes interrupt the ERK1/2-HIF-1α-p300/CREB axis in mice intoxicated with diethylnitrosamine: A new paradigm in drug repurposing for the inhibition of hepatocellular carcinoma progression.
    Saber S; Nasr M; Saad AS; Mourad AAE; Gobba NA; Shata A; Hafez AM; Elsergany RN; Elagamy HI; El-Ahwany E; Amin NA; Girgis S; Elewa YHA; Mahmoud MH; Batiha GE; El-Rous MA; Kamal I; Kaddah MMY; Khodir AE
    Biomed Pharmacother; 2021 Oct; 142():112029. PubMed ID: 34416629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of peroxisome proliferator-activated receptor-gamma inhibits tumor growth by negatively regulating nuclear factor-κB activation in patients with hepatocellular carcinoma.
    Nojima H; Kuboki S; Shinoda K; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Takayashiki T; Miyazaki M
    J Hepatobiliary Pancreat Sci; 2016 Sep; 23(9):574-84. PubMed ID: 27451128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of transforming growth factor-activated kinase-1 on tumor necrosis factor-α actions in human adipose tissue-derived stromal cells.
    Lee SY; Lee JH; Shin KK; Kim DS; Kim YS; Bae YC; Jung JS
    Stem Cells Dev; 2015 Apr; 24(7):836-45. PubMed ID: 25350220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway.
    Zhang N; Chu ES; Zhang J; Li X; Liang Q; Chen J; Chen M; Teoh N; Farrell G; Sung JJ; Yu J
    Oncotarget; 2014 Sep; 5(18):8330-40. PubMed ID: 25327562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the
    Zhang J; Chen Y; Lin J; Jia R; An T; Dong T; Zhang Y; Yang X
    DNA Cell Biol; 2020 Mar; 39(3):355-367. PubMed ID: 31913706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1.
    Yang PW; Lu ZY; Pan Q; Chen TT; Feng XJ; Wang SM; Pan YC; Zhu MH; Zhang SH
    Phytomedicine; 2019 Apr; 57():18-29. PubMed ID: 30668319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
    Yang C; Qin S
    Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4.
    Shu Y; Lu Y; Pang X; Zheng W; Huang Y; Li J; Ji J; Zhang C; Shen P
    Oncotarget; 2016 Nov; 7(47):76984-76994. PubMed ID: 27769068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest.
    Oura K; Tadokoro T; Fujihara S; Morishita A; Chiyo T; Samukawa E; Yamana Y; Fujita K; Sakamoto T; Nomura T; Yoneyama H; Kobara H; Mori H; Iwama H; Okano K; Suzuki Y; Masaki T
    Oncol Rep; 2017 Nov; 38(5):2825-2835. PubMed ID: 29048654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
    Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
    Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma.
    Li N; Luo L; Wei J; Liu Y; Haque N; Huang H; Qi Y; Huang Z
    Int J Biol Macromol; 2021 Jul; 182():910-920. PubMed ID: 33865893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TIPE2 inhibits TNF-α-induced hepatocellular carcinoma cell metastasis via Erk1/2 downregulation and NF-κB activation.
    Zhang YH; Yan HQ; Wang F; Wang YY; Jiang YN; Wang YN; Gao FG
    Int J Oncol; 2015 Jan; 46(1):254-64. PubMed ID: 25339267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma.
    Vara D; Morell C; Rodríguez-Henche N; Diaz-Laviada I
    Cell Death Dis; 2013 May; 4(5):e618. PubMed ID: 23640460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.